Process of production of liposomes, product thus obtained and its uses

Process of production of liposomes, product thus obtained and its uses

NOVELTY – Producing liposome involves filling aqueous solution into reactor equipped with baffles. Mechanical agitation of the aqueous solution is carried out between 9600-15000 revolutions per minute. The obtained solution is added with ethanolic suspension (62.5mol/L) of egg phosphatidylcholine, 1,2-dioleoyl-3-trimethylammonium propane and 1-a-dioleoyl phosphatidylethanolamine in ratio of 50:25:25 to obtain mixture. The mixture is added to the reactor and stirred at rate of 38-50ml/minute until final lipid concentration reaches to value between 2.0-4.8mmol/L. Mechanical stirring is carried out. USE – Method for producing liposome used for activating or transfecting cells which internalize nanoparticles by macropinoitose or phagocytosis, such as dendritic cells are used for gene vaccination or immunotherapy, and carrying mixture of tumor cell RNA, preferably total RNA of SK-BR-3 cells (human breast adenocarcinoma) that overexpress human epidermal growth factor-2 protooncogene/neu (all claimed). DETAILED DESCRIPTION – Producing liposome involves filling aqueous solution into reactor equipped with baffles. Mechanical agitation of the aqueous solution is carried out between 9600-15000 revolutions per minute. The obtained solution is added with ethanolic suspension (62.5mol/L) of egg phosphatidylcholine, 1,2-dioleoyl-3-trimethylammonium propane and 1-a-dioleoyl phosphatidylethanolamine in ratio of 50:25:25 to obtain mixture. The mixture is added to the reactor and stirred at rate of 38-50ml/minute until final lipid concentration reaches to value between 2.0-4.8mmol/L. Mechanical stirring is carried out to obtain dispersion for 5 minutes after end of injection.

Main Application Field

B07 (General – tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); D16 (Fermentation industry – including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)

INVENTORS:

BARBUTO JOSÉ ALEXANDRE MARZAGÃO
TORRE LUCIMARA GAZIOLA DE LA
VITOR MICAELA TAMARA
BERGAMI-SANTOS PATRICIA CRUZ

735_IMUNOTERAPIA

Patent number: BR102013027699-A2

PATENT STATUS:

For information contact Inova Unicamp

FOR ADDITIONAL INFORMATION:

parcerias@inova.unicamp.br

+55 (19) 3521-5207 / 2607

This technology profile has been automatically generated.

COMPARTILHE:

TECNOLOGIAS RELACIONADAS: